GLP-1 receptor agonists

At a time when more than one billion people are living with obesity,GLP-1s are widely viewed as among the biggest advances in obesity treatment. But one important question is becoming harder to avoid: what happens when people stop taking them?

GLP-1 drugs like Ozempic and Wegovy are already known for treating type 2 diabetes and helping with weight loss. Now, a new study suggests they may also improve some of the most difficult complications to treat in type 2 diabetes.

A modified diet that takes cues from the Mediterranean model has the potential to promote healthier aging, with scientists using a large dataset from human records and combining it with an animal study to work out just why this could be.

A once-a-day oral GLP-1 pill known as CX11 has met its dosage and efficacy goals in a trial on US patients and will now advance to its first North American Phase 3 trial. It's already cleared this final hurdle in China where it awaits approval.

A new study suggests the drug’s influence over our brain’s control systems may attenuate behaviors linked to aggression, which, given the widespread use of these pharmaceuticals, could ultimately dampen the rate of violent crime.

Scientists have identified a new way to supercharge obesity drug semaglutide by targeting key neurons. It could dramatically boost GLP-1 weight-loss power and prevent the dreaded plateaus that not even this "wonder drug" has been able to circumvent.

Could glucagon-like peptide-1 receptor agonists (GLP-1 RAs) nix the inflammation that drives asthma? Maybe, according to a large national study of more than 27,000 older adults, which was presented to scientists last week.

A new study has shown that the popular GLP-1 weight loss drug semaglutide has the power to halt, and to some extent restore, cartilage in people suffering from osteoarthritis (OA). The finding hints at a possible use of the drug beyond weight loss.

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking GLP-1s regain the pounds and return to their original size after 1.7 years. It questions whether we're relying on this "magic cure" too heavily.

The rise in popularity of GLP-1 receptor agonist drugs like Ozempic is causing a wider societal shift that is now rocking the food industry. And some are feeling the pain more than others, as people make fundamental changes to their lives and health.

The World Health Organization has finally made its recommendations on using GLP-1 therapeutics for weight loss, though it remains to be seen whether it changes their status for prescribing or price. And scientists still have some concerns.

Scientists have failed to show that weight-loss wonder drug semaglutide can also slow the progress of Alzheimer's disease (AD), as two two-year clinical trials end in disappointment for patients, medical scientists and drugmaker Novo Nordisk.